Role Of Hiv Disease In The Pathogenesis Of Hepatitis B

艾滋病毒疾病在乙型肝炎发病机制中的作用

• 批准号: 6507015
• 负责人: Anthony S. Fauci
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6507015
• 关键词: AIDS therapy; HIV infections; adefovir; comorbidity; drug resistance; hepatitis B; hepatitis B virus group; human immunodeficiency virus; human subject; human therapy evaluation; lamivudine; liver cirrhosis; pathologic process; patient oriented research; tissue /cell culture; virus load

HIV related opportunistic infections have declined significantly as a result of anti-retroviral therapy. However, other serious medical diseases, such as advanced liver disease, have become an important area of concern in the clinical care of HIV-infected individuals. In this regard, HIV infection is thought to have a negative impact on the progression of liver disease as a result of chronic hepatitis B virus (HBV) infection. Unfortunately, many individuals with HBV disease fail first-line therapy with lamivudine. Adefovir dipivoxil may offer a therapeutic option to HIV- infected individuals who are co-infected with HBV who have failed lamivudine therapy. LIR investigators have recently opened two clinical trials assessing the safety and efficacy of low-dose adefovir (10 mg daily) for the treatment of chronic hepatitis B in HIV-infected individuals who have HBV-related liver disease and persistent HBV plasma viremia despite lamivudine therapy. In addition to evaluating the clinical safety and efficacy of adefovir, we are investigating the impact of HIV infection on HBV-specific cellular immune function. These studies will expand our understanding of the pathogenesis and treatment of HBV disease in HIV-infected people.

由于抗逆转录病毒治疗，艾滋病毒相关的机会性感染已显着下降。然而，其他严重的医学疾病，例如晚期肝病，已成为艾滋病毒感染者临床护理中的一个重要关注领域。在这方面，HIV 感染被认为对慢性乙型肝炎病毒 (HBV) 感染导致的肝病进展具有负面影响。不幸的是，许多患有 HBV 疾病的人在拉米夫定一线治疗中失败。阿德福韦酯可为拉米夫定治疗失败的同时感染 HBV 的 HIV 感染者提供一种治疗选择。 LIR 研究人员最近启动了两项临床试验，评估低剂量阿德福韦（每天 10 毫克）治疗 HIV 感染者慢性乙型肝炎的安全性和有效性，这些感染者尽管接受拉米夫定治疗，但仍患有 HBV 相关肝病和持续性 HBV 血浆病毒血症。除了评估阿德福韦的临床安全性和有效性外，我们还在研究HIV感染对HBV特异性细胞免疫功能的影响。这些研究将扩大我们对 HIV 感染者 HBV 疾病发病机制和治疗的了解。